Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort

Weijie Cao,&ast; Yiting Xu,&ast; Yun Shen, Yufei Wang, Xiaojing Ma, Yuqian Bao Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Dia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cao W, Xu Y, Shen Y, Wang Y, Ma X, Bao Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	metabolism-associated fatty liver disease fibroblast growth factor 23 liver fat content diabetes Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c6fed040f432450c9ee335a525080c0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6fed040f432450c9ee335a525080c0a
record_format	dspace
spelling	oai:doaj.org-article:c6fed040f432450c9ee335a525080c0a2021-12-02T17:29:56ZSerum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort1178-7007https://doaj.org/article/c6fed040f432450c9ee335a525080c0a2021-09-01T00:00:00Zhttps://www.dovepress.com/serum-fibroblast-growth-factor-23-level-and-liver-fat-content-in-mafld-peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Weijie Cao,&ast; Yiting Xu,&ast; Yun Shen, Yufei Wang, Xiaojing Ma, Yuqian Bao Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Diabetes Institute; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, 200233, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xiaojing Ma; Yuqian BaoDepartment of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai, 200233, People’s Republic of ChinaTel +86-21-64369181Fax +86-21-64368031Email maxiaojing@sjtu.edu.cn; yqbao@sjtu.edu.cnPurpose: Although fibroblast growth factor-23 (FGF23) is involved in the development of metabolic diseases, its association with metabolic-associated fatty liver disease (MAFLD) remains unknown. We explored the relationship between serum fibroblast growth factor-23 level, metabolic associated fatty liver disease, and liver fat content.Patients and Methods: Participants were enrolled from communities in Shanghai. Serum fibroblast growth factor-23 level was determined using two-side sandwich enzyme-linked immunosorbent assays. MAFLD was diagnosed using the international expert consensus (2020) criteria. Liver fat content was assessed using ultrasound.Results: We enrolled 1827 individuals aged 30– 80 years (mean age, 59.4± 7.3 years). MAFLD was diagnosed in 445/1393 (31.9%) non-diabetic participants and 245/434 (56.5%) diabetic participants. After adjusting for confounders, one standard deviation increase in serum FGF23 was associated with MAFLD in diabetic (odds ratio, 1.27; 95% confidence interval, 1.15– 1.49; P< 0.001) and non-diabetic (odds ratio, 1.28; 95% confidence interval, 1.07– 1.74; P=0.030) groups. In a fully adjusted linear regression model, serum FGF23 emerged as a positive determinant of liver fat content in both diabetic and non-diabetic groups (P=0.039; P=0.034).Conclusion: Participants with MAFLD had higher serum fibroblast growth factor-23 level than those without MAFLD, regardless of diabetes status. Serum fibroblast growth factor-23 was independently related to MAFLD and liver fat content.Keywords: metabolism-associated fatty liver disease, fibroblast growth factor 23, liver fat content, diabetesCao WXu YShen YWang YMa XBao YDove Medical Pressarticlemetabolism-associated fatty liver diseasefibroblast growth factor 23liver fat contentdiabetesSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 4135-4143 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metabolism-associated fatty liver disease fibroblast growth factor 23 liver fat content diabetes Specialties of internal medicine RC581-951
spellingShingle	metabolism-associated fatty liver disease fibroblast growth factor 23 liver fat content diabetes Specialties of internal medicine RC581-951 Cao W Xu Y Shen Y Wang Y Ma X Bao Y Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
description	Weijie Cao,&ast; Yiting Xu,&ast; Yun Shen, Yufei Wang, Xiaojing Ma, Yuqian Bao Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Diabetes Institute; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, 200233, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xiaojing Ma; Yuqian BaoDepartment of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai, 200233, People’s Republic of ChinaTel +86-21-64369181Fax +86-21-64368031Email maxiaojing@sjtu.edu.cn; yqbao@sjtu.edu.cnPurpose: Although fibroblast growth factor-23 (FGF23) is involved in the development of metabolic diseases, its association with metabolic-associated fatty liver disease (MAFLD) remains unknown. We explored the relationship between serum fibroblast growth factor-23 level, metabolic associated fatty liver disease, and liver fat content.Patients and Methods: Participants were enrolled from communities in Shanghai. Serum fibroblast growth factor-23 level was determined using two-side sandwich enzyme-linked immunosorbent assays. MAFLD was diagnosed using the international expert consensus (2020) criteria. Liver fat content was assessed using ultrasound.Results: We enrolled 1827 individuals aged 30– 80 years (mean age, 59.4± 7.3 years). MAFLD was diagnosed in 445/1393 (31.9%) non-diabetic participants and 245/434 (56.5%) diabetic participants. After adjusting for confounders, one standard deviation increase in serum FGF23 was associated with MAFLD in diabetic (odds ratio, 1.27; 95% confidence interval, 1.15– 1.49; P< 0.001) and non-diabetic (odds ratio, 1.28; 95% confidence interval, 1.07– 1.74; P=0.030) groups. In a fully adjusted linear regression model, serum FGF23 emerged as a positive determinant of liver fat content in both diabetic and non-diabetic groups (P=0.039; P=0.034).Conclusion: Participants with MAFLD had higher serum fibroblast growth factor-23 level than those without MAFLD, regardless of diabetes status. Serum fibroblast growth factor-23 was independently related to MAFLD and liver fat content.Keywords: metabolism-associated fatty liver disease, fibroblast growth factor 23, liver fat content, diabetes
format	article
author	Cao W Xu Y Shen Y Wang Y Ma X Bao Y
author_facet	Cao W Xu Y Shen Y Wang Y Ma X Bao Y
author_sort	Cao W
title	Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
title_short	Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
title_full	Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
title_fullStr	Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
title_full_unstemmed	Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort
title_sort	serum fibroblast growth factor 23 level and liver fat content in mafld: a community-based cohort
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c6fed040f432450c9ee335a525080c0a
work_keys_str_mv	AT caow serumfibroblastgrowthfactor23levelandliverfatcontentinmafldacommunitybasedcohort AT xuy serumfibroblastgrowthfactor23levelandliverfatcontentinmafldacommunitybasedcohort AT sheny serumfibroblastgrowthfactor23levelandliverfatcontentinmafldacommunitybasedcohort AT wangy serumfibroblastgrowthfactor23levelandliverfatcontentinmafldacommunitybasedcohort AT max serumfibroblastgrowthfactor23levelandliverfatcontentinmafldacommunitybasedcohort AT baoy serumfibroblastgrowthfactor23levelandliverfatcontentinmafldacommunitybasedcohort
_version_	1718380754045501440

Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort

Ejemplares similares